The data raise questions about valve hemodynamics and the role of early imaging to stay ahead of clinical and subclinical ...
Medtronic reported 4.1% organic revenue growth and 6.2% adjusted EPS growth. See why we upgraded MDT stock to 'Buy' with a ...
In the West, the practice of exchanging rings to mark a betrothal dates back to ancient Rome, when noble families would trade ...
Medtronic released positive two-year trial Evolut TAVR results that demonstrated superior valve performance in small aortic ...
10 天
Medical Device Network on MSNMedtronic announces two-year trial outcomes of Evolut TAVRMedtronic has announced the SMART trial’s two-year outcomes of Evolut TAVR for aortic stenosis (AS) and small aortic annulus.
Medtronic plc released positive results from a two-year trial of Evolut TAVR that demonstrated superior valve performance in patients with small aortic annuli.
Medtronic (MDT) released the two-year results of the SMall Annuli Randomized To Evolut or SAPIEN, SMART, Trial, the largest international ...
The following is a summary of "Transcatheter Aortic Valve Replacement Beyond Severe Aortic Stenosis: JACC State-of-the-Art ...
9 天
Zacks.com on MSNPositive Trial Data on Evolut TAVR Likely to Support MDT StockAt the CRT conference 2025, Medtronic presented two-year favorable SMART trial data, which demonstrated the superior performance of the Evolut TAVR valve in patients with AS.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果